Supernus Pharmaceuticals, a specialty pharmaceutical company focused on developing and commercializing products for the treatment of CNS disease, sannounced that it sued generic drug makers Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (collectively “Zydus”) for infringement of three patents covering its antiepileptic drug Trokendi XR. Supernus’ United States Patents Nos. 8,298,576, 8,298,580, and 8,663,683 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR does not expire until 2029.
Help employers find you! Check out all the jobs and post your resume.
